

# Amyloid PET Depleted Patients After Anti-Amyloid Therapies

## Workgroup members

Renaud La Joie\*, Claire Sexton\*, Maria Carrillo, Jeffrey L. Cummings, Douglas Galasko, Milos D. Ikonomovic, Susan M. Landau, Jorge Llibre-Guerra, Catherine Mummery, Rik Ossenkoppele, Julie Price, Shannon Risacher, Ruben Smith, Christopher H. van Dyck.

\*[renaud.lajoie@ucsf.edu](mailto:renaud.lajoie@ucsf.edu), [csexton@alz.org](mailto:csexton@alz.org)

## Background

- Anti-amyloid therapies have a major effect on amyloid-PET.
- In phase 2 and 3 trials, many patients have become amyloid-PET negative after treatment.
- The observed effect on amyloid PET is thought to underpin clinical benefit.
- In donanemab phase 2 and 3 trials, set criteria for amyloid-PET negativity in previously amyloid-PET positive patients led to the patient being switched to placebo.

## Specific issues and workgroup goals

### Issues

- There is major heterogeneity in the definition and reporting of cases across studies, with cases identified based on PET quantification with threshold (SUVR, Centiloid) or visual read.
- As a result, there is a need for a specific name for this new entity of amyloid-negative patients with Alzheimer's disease.

### Goals of the workgroup

- To summarize current knowledge about "amyloid-depleted" cases.
- To define a framework for:
  - a harmonized definition and operationalization for future studies.
  - a nomenclature for this new entity.


## Scope of work

Our current focus is on:

- Data available in disease modifying therapies in cognitively impaired patients (not preclinical AD).
- Defining group based on amyloid-PET (not other biomarkers):
  - PET has been the gold standard in trials so far.
  - PET quantification is more harmonized than CSF/plasma measures.
  - Changes in biofluid biomarkers have been reported, but not with the same level of detail as PET.
  - We plan to document the currently known course of fluid biomarker changes in our report.

## Implementation: Proposed 3-tier classification

Suggestions for standard reporting in research studies, clinical trials and clinical practice (when data available).



## DRAFT for public feedback

### Define a positivity threshold?

Amyloid deposition is a continuous process and studies have shown "subthreshold effects" at the group level. But thresholds would allow ease of employment and cross-comparison across clinical trials, research studies and clinical settings, similar to what the AT(N)/NIA-AA framework did.

To determine thresholds that could be usable across contexts of use, the workgroup considered threshold(s) reported in the literature based on various gold standards.

- Thresholds to define amyloid positivity in observational studies and trials:
  - ADNI (18-20, see [Royse 2021](#))
  - AHEAD A3 inclusion > 20 ([intermediate amyloid range defined as \[20-40\]](#))
- Centiloid values corresponding to visual read
  - 16 [Matsuda 2021](#)
  - 17 [Collij 2021](#)
  - 21 [Collij 2023](#)
  - 24.6 (IDEAS, CTAD23)
- Data driven approaches
  - 19 - reliable worsening cut point (Mayo) [Jack 2017](#)
- Thresholds used in anti-amyloid trials to define amyloid negativity after treatment:
  - Aducanemab (ENGAGE/EMERGE): 20.2 CL (CTAD 2023)
  - Lecanemab (Clarity-AD): 30 [Van Dyck 2023](#)
  - Donanemab (Trailblazer-Alz2): 24.1 [Sims 2023](#)

**Thresholds seem to converge around 20 CL, but similar to the AT(N) framework, individual groups will be able to apply their own method.**

### Regarding implementation

Implementation could be relatively easy in research studies and trials, as Centiloids are now widely used.

However, there would be multiple issues in clinical settings, as

- Questions remain regarding collection of longitudinal scans clinically
- Amyloid-PET is currently only approved for visual (binary read); no quantification method is currently approved.
- With regard to the visual interpretation of post DMT Amyloid-PET, it is not yet known if there are any specific characteristics to consider when visually interpreting a post-DMT scan? I.e., are they similar to 'wildtype' amyloid negative scans? Do ARIA impact PET tracer binding?

## DRAFT for public feedback

### Nomenclature (work in progress)

3 components are being considered for naming, to indicate:

- Change compared to prior
  - *Change / Depletion / Reduced / Clearance*
- Change in response to treatment
  - *Treatment-induced / Following treatment / After treatment / Response*
- Change is in biomarker, not necessarily pathology
  - *Amyloid biomarker* or specific to modality (PET versus fluid)

Examples of terms that combine all components:

*"Treatment-Induced Amyloid Biomarker Depletion"*  
*"Reduced Amyloid Biomarker After Treatment"...*

An umbrella term to more broadly describe individuals who display changes in biomarkers following treatment is also under consideration.

### Current evidence and gaps in knowledge

Questions remain regarding

- The underlying neuropathology: very limited data.
- The relationship with biofluid markers.
  - Difference in time course? Are fluid biomarkers "normalizing" like PET does?
- Predictors of Amyloid-PET depletion?
  - From (few) publications: baseline Amyloid levels, treatment dose and duration.
- Factors associated with Amyloid-PET depletion.
  - Clinical response, future change in biomarkers.
- The management of amyloid depleted patients?
  - Adapt treatment duration?
  - Enrollment in other trials?
  - Relevance to combination approach?

### Feedback is needed

We invite comments and feedback, particularly seeking suggestions regarding:

- the relevance and usefulness of the 3-tiers classification framework ([Proposed 3-tier classification](#))
- the possibility of defining a harmonized threshold for amyloid-PET negativity following treatment ([Define a positivity threshold?](#))
- the name of this entity ([Nomenclature](#))